S Anttila, J Hukkanen, J Hakkola, T Stjernvall, P Beaune, RJ Edwards, AR Boobis, O Pelkonen and H Raunio
Finnish Institute of Occupational Health, Helsinki. sant@occuphealth.fi

Expression in the lung of procarcinogen-metabolizing P450 enzymes in the CYP3A subfamily may contribute to the initiation of pulmonary carcinogenesis by agents that require metabolic activation, such as tobacco-derived polycyclic aromatic hydrocarbons. Expression and localization of CYP3A4 and CYP3A5 proteins in human lung were determined by immunohistochemistry with three antibodies, one specific for members of the CYP3A subfamily and two antipeptide antibodies specific for CYP3A4 and CYP3A5, respectively. Positive immunostaining in one or several cell types of the lung was observed in all patients with anti-CYP3A4 and anti-CYP3A5 antibodies. With the anti-CYP3A4 antibody epithelial staining was observed in five cases and staining of alveolar macrophages in 12 of 27 cases. To determine which CYP3A genes are transcribed in lung tissue, analysis by reverse-transcriptase- polymerase chain reaction with gene-specific primers for CYP3A4, CYP3A5, and CYP3A7 was performed. CYP3A5 mRNA was detected in all eight samples studied, CYP3A4 mRNA in one sample, and CYP3A7 mRNA in none of the samples. CYP3A5 was localized by immunohistochemistry in the ciliated and mucous cells of the bronchial wall, bronchial glands, bronchiolar columnar and terminal cuboidal epithelium, type I and type II alveolar epithelium, vascular and capillary endothelium, and alveolar macrophages, whereas CYP3A4 was found in bronchial glands, bronchiolar columnar and terminal epithelium, type II alveolar epithelium, and alveolar macrophages. These data establish that CYP3A5 is the predominant CYP3A form in human lung, that CYP3A4 is expressed in about 20% of individuals, and considerable variation of pulmonary expression occurs in both CYPs between individuals.

This article has been cited by other articles:

				H. Jin, J. Dai, X. Chen, J. Liu, D. Zhong, Y. Gu, and J. Zheng Pulmonary Toxicity and Metabolic Activation of Dauricine in CD-1 Mice J. Pharmacol. Exp. Ther., March 1, 2010; 332(3): 738 - 746. [Abstract] [Full Text] [PDF]

				G. I. Somers, N. Lindsay, B. M. Lowdon, A. E. Jones, C. Freathy, S. Ho, A. J. M. Woodrooffe, M. K. Bayliss, and G. R. Manchee A Comparison of the Expression and Metabolizing Activities of Phase I and II Enzymes in Freshly Isolated Human Lung Parenchymal Cells and Cryopreserved Human Hepatocytes Drug Metab. Dispos., October 1, 2007; 35(10): 1797 - 1805. [Abstract] [Full Text] [PDF]

				J. S. Biggs, J. Wan, N. S. Cutler, J. Hakkola, P. Uusimaki, H. Raunio, and G. S. Yost Transcription Factor Binding to a Putative Double E-Box Motif Represses CYP3A4 Expression in Human Lung Cells Mol. Pharmacol., September 1, 2007; 72(3): 514 - 525. [Abstract] [Full Text] [PDF]

				A.-M. Moilanen, J. Hakkola, M. H. Vaarala, S. Kauppila, P. Hirvikoski, J. T. Vuoristo, R. J. Edwards, and T. K. Paavonen Characterization of androgen-regulated expression of CYP3A5 in human prostate Carcinogenesis, May 1, 2007; 28(5): 916 - 921. [Abstract] [Full Text] [PDF]

				K. C. Day, C. G. Plopper, and M. V. Fanucchi Age-specific pulmonary cytochrome P-450 3A1 expression in postnatal and adult rats Am J Physiol Lung Cell Mol Physiol, July 1, 2006; 291(1): L75 - L83. [Abstract] [Full Text] [PDF]

				R. E. Pearce, J. S. Leeder, and G. L. Kearns BIOTRANSFORMATION OF FLUTICASONE: IN VITRO CHARACTERIZATION Drug Metab. Dispos., June 1, 2006; 34(6): 1035 - 1040. [Abstract] [Full Text] [PDF]

				J. Borlak, M. Blickwede, T. Hansen, W. Koch, M. Walles, and K. Levsen METABOLISM OF VERAPAMIL IN CULTURES OF RAT ALVEOLAR EPITHELIAL CELLS AND PHARMACOKINETICS AFTER ADMINISTRATION BY INTRAVENOUS AND INHALATION ROUTES Drug Metab. Dispos., August 1, 2005; 33(8): 1108 - 1114. [Abstract] [Full Text] [PDF]

				P. P. Medina, J. Carretero, E. Ballestar, B. Angulo, F. Lopez-Rios, M. Esteller, and M. Sanchez-Cespedes Transcriptional targets of the chromatin-remodelling factor SMARCA4/BRG1 in lung cancer cells Hum. Mol. Genet., April 1, 2005; 14(7): 973 - 982. [Abstract] [Full Text] [PDF]

				K. Matsumura, T. Saito, Y. Takahashi, T. Ozeki, K. Kiyotani, M. Fujieda, H. Yamazaki, H. Kunitoh, and T. Kamataki Identification of a Novel Polymorphic Enhancer of the Human CYP3A4 Gene Mol. Pharmacol., February 1, 2004; 65(2): 326 - 334. [Abstract] [Full Text] [PDF]

				R. J. Edwards, A. R. Boobis, and D. S. Davies A STRATEGY FOR INVESTIGATING THE CYP SUPERFAMILY USING TARGETED ANTIBODIES IS A PARADIGM FOR FUNCTIONAL GENOMIC STUDIES Drug Metab. Dispos., December 1, 2003; 31(12): 1476 - 1480. [Abstract] [Full Text] [PDF]

				J. A. Williams, J. Cook, and S. I. Hurst A SIGNIFICANT DRUG-METABOLIZING ROLE FOR CYP3A5? Drug Metab. Dispos., December 1, 2003; 31(12): 1526 - 1530. [Abstract] [Full Text] [PDF]

				G. B. J. Smith, J. R. Bend, L. L. Bedard, K. R. Reid, D. Petsikas, and T. E. Massey BIOTRANSFORMATION OF 4-(METHYLNITROSAMINO)-1-(3-PYRIDYL)-1-BUTANONE (NNK) IN PERIPHERAL HUMAN LUNG MICROSOMES Drug Metab. Dispos., September 1, 2003; 31(9): 1134 - 1141. [Abstract] [Full Text] [PDF]

				B. A. Carr, J. Wan, R. N. Hines, and G. S. Yost Characterization of the Human Lung CYP2F1 Gene and Identification of a Novel Lung-specific Binding Motif J. Biol. Chem., April 25, 2003; 278(18): 15473 - 15483. [Abstract] [Full Text] [PDF]

				J. Hukkanen, T. Vaisanen, A. Lassila, R. Piipari, S. Anttila, O. Pelkonen, H. Raunio, and J. Hakkola Regulation of CYP3A5 by Glucocorticoids and Cigarette Smoke in Human Lung-Derived Cells J. Pharmacol. Exp. Ther., February 1, 2003; 304(2): 745 - 752. [Abstract] [Full Text] [PDF]

				W. K. Nichols, R. Mehta, K. Skordos, K. Mace, A. M. A. Pfeifer, B. A. Carr, T. Minko, S. W. Burchiel, and G. S. Yost 3-Methylindole-Induced Toxicity to Human Bronchial Epithelial Cell Lines Toxicol. Sci., February 1, 2003; 71(2): 229 - 236. [Abstract] [Full Text] [PDF]

				Y. S. Lin, A. L. S. Dowling, S. D. Quigley, F. M. Farin, J. Zhang, J. Lamba, E. G. Schuetz, and K. E. Thummel Co-Regulation of CYP3A4 and CYP3A5 and Contribution to Hepatic and Intestinal Midazolam Metabolism Mol. Pharmacol., July 1, 2002; 62(1): 162 - 172. [Abstract] [Full Text] [PDF]

				J. Hukkanen, O. Pelkonen, and H. Raunio Expression of xenobiotic-metabolizing enzymes in human pulmonary tissue: possible role in susceptibility for ILD Eur. Respir. J., July 1, 2001; 18(32_suppl): 122S - 126s. [Abstract] [Full Text] [PDF]

				J. Hukkanen, A. Lassila, K. Paivarinta, S. Valanne, S. Sarpo, J. Hakkola, O. Pelkonen, and H. Raunio Induction and Regulation of Xenobiotic-Metabolizing Cytochrome P450s in the Human A549 Lung Adenocarcinoma Cell Line Am. J. Respir. Cell Mol. Biol., March 1, 2000; 22(3): 360 - 366. [Abstract] [Full Text]

				R. K. Stewart, G. B.J. Smith, P. J. Donnelly, K. R. Reid, D. Petsikas, A.A. Conlan, and T. E. Massey Glutathione S-transferase-catalyzed conjugation of bioactivated aflatoxin B1 in human lung: differential cellular distribution and lack of significance of the GSTM1 genetic polymorphism Carcinogenesis, October 1, 1999; 20(10): 1971 - 1977. [Abstract] [Full Text] [PDF]

				G. B.J. Smith, A. Castonguay, P. J. Donnelly, K. R. Reid, D. Petsikas, and T. E. Massey Biotransformation of the tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in freshly isolated human lung cells Carcinogenesis, September 1, 1999; 20(9): 1809 - 1818. [Abstract] [Full Text] [PDF]

				D. SPINA Epithelium Smooth Muscle Regulation and Interactions Am. J. Respir. Crit. Care Med., November 1, 1998; 158(2007): S141 - S145. [Abstract] [Full Text] [PDF]